GlassScriptPhysician profile
Karl Kruszynski
NPI 1992810220
$7,227.51
in general payments reported to CMS, 2019-2025
26 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $1,513 · 2023: $1,619 · 2024: $2,125 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,822 · Education: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,821.80 |
| Education | $547.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,462.40 | 2021-2025 | |
| Janssen Biotech, INC. | $1,095.06 | 2022-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $602.96 | 2021-2025 | |
| Incyte Corporation | $587.15 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $446.66 | 2023-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $445.40 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $360.20 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $357.77 | 2022-2025 | |
| Dermavant Sciences, INC. | $273.83 | 2022-2024 | Vtama |
| Ucb, INC. | $264.92 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $235.02 | 2021-2024 | Otezla |
| Leo Pharma INC. | $164.48 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $163.89 | 2022-2024 | Winlevi, Absorica Ld, Ilumya |
| Arcutis Biotherapeutics, INC. | $132.21 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $125.68 | 2023-2025 | Aklief, Nemluvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $107.59 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Biofrontera INC. | $49.84 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Fresenius Kabi USA, LLC | $46.13 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.94 | 2024 | Spevigo |
| Journey Medical Corporation | $37.68 | 2022 | |
| Paratek Pharmaceuticals, INC. | $34.35 | 2025 | Nuzyra |
| Helsinn Therapeutics (U.S.), INC. | $26.29 | 2023 | Valchlor |
| Almirall LLC | $24.36 | 2022 | |
| Organon LLC | $23.67 | 2025 | |
| Cipher Pharmaceuticals US LLC | $14.04 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Kruszynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.